SCHEMBL2482391

SCHEMBL2482391

COc1cc(Nc2cc(NCc3cc(F)cc(F)c3)c(C(N)=O)cn2)ccc1N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.60
STAT6 P42226 7/20 0.55
MAPK9 P45984 2/20 0.52
MAPK8 P45983 1/20 0.52
TNIK Q9UKE5 4/20 0.51
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KCNH2 Q12809 2/20 0.46
JAK3 P52333 2/20 0.46
IRAK4 Q9NWZ3 2/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
SYK P43405 2/20 0.45
ZAP70 P43403 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476526 0.90 MAPK10 (0.58) MAPK10STAT6MAPK9GAAJAK3
SCHEMBL2478742 0.89 STAT6 (0.57) MAPK10STAT6MAPK9GAASMN1; SMN2
SCHEMBL2479159 0.88 STAT6 (0.58) MAPK10STAT6MAPK9JAK3IRAK4
SCHEMBL2479544 0.86 STAT6 (0.55) MAPK10STAT6MAPK9GAAJAK3
SCHEMBL2481818 0.86 STAT6 (0.72) MAPK10STAT6MAPK9JAK3IRAK4
SCHEMBL12301484 0.86 STAT6 (0.55) MAPK10STAT6MAPK9GAAJAK3
SCHEMBL2479353 0.85 MAPK10 (0.58) MAPK10STAT6MAPK9MAPK8ZAP70
SCHEMBL2478938 0.83 STAT6 (0.61) MAPK10STAT6MAPK9JAK3IRAK4
SCHEMBL12301469 0.82 STAT6 (0.64) MAPK10STAT6MAPK9JAK3IRAK4
SCHEMBL2478723 0.81 STAT6 (0.61) MAPK10STAT6MAPK9JAK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US claimed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP claimed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US claimed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA MAPK10 310/4885STAT6 8/4885MAPK9 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.